Rhumbline Advisers decreased its holdings in GlycoMimetics Inc (NASDAQ:GLYC) by 2.8% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 43,318 shares of the biotechnology company’s stock after selling 1,242 shares during the quarter. Rhumbline Advisers’ holdings in GlycoMimetics were worth $540,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of GLYC. Dimensional Fund Advisors LP boosted its stake in shares of GlycoMimetics by 58.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 617,420 shares of the biotechnology company’s stock valued at $5,847,000 after purchasing an additional 228,664 shares during the period. Hudson Bay Capital Management LP boosted its stake in shares of GlycoMimetics by 105.9% in the fourth quarter. Hudson Bay Capital Management LP now owns 350,000 shares of the biotechnology company’s stock valued at $3,315,000 after purchasing an additional 180,000 shares during the period. Squarepoint Ops LLC boosted its stake in shares of GlycoMimetics by 259.3% in the fourth quarter. Squarepoint Ops LLC now owns 84,115 shares of the biotechnology company’s stock valued at $797,000 after purchasing an additional 60,701 shares during the period. Geode Capital Management LLC boosted its stake in shares of GlycoMimetics by 16.2% in the fourth quarter. Geode Capital Management LLC now owns 412,003 shares of the biotechnology company’s stock valued at $3,901,000 after purchasing an additional 57,392 shares during the period. Finally, Citigroup Inc. boosted its stake in shares of GlycoMimetics by 45.4% in the fourth quarter. Citigroup Inc. now owns 114,809 shares of the biotechnology company’s stock valued at $1,087,000 after purchasing an additional 35,826 shares during the period.

GlycoMimetics stock traded down $0.16 during trading on Wednesday, reaching $10.57. The stock had a trading volume of 5,436 shares, compared to its average volume of 221,231. GlycoMimetics Inc has a 52-week low of $8.29 and a 52-week high of $18.20. The company has a quick ratio of 23.88, a current ratio of 23.88 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $456.37 million, a P/E ratio of -8.96 and a beta of 2.64.

GlycoMimetics (NASDAQ:GLYC) last issued its quarterly earnings results on Thursday, May 2nd. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.01. As a group, research analysts anticipate that GlycoMimetics Inc will post -1.18 earnings per share for the current fiscal year.

Several research firms have recently commented on GLYC. BidaskClub lowered shares of GlycoMimetics from a “buy” rating to a “hold” rating in a research note on Wednesday, May 1st. Zacks Investment Research upgraded shares of GlycoMimetics from a “hold” rating to a “buy” rating and set a $14.00 price target for the company in a research note on Wednesday, May 8th. Finally, Piper Jaffray Companies began coverage on shares of GlycoMimetics in a research note on Friday, April 12th. They issued an “overweight” rating and a $20.00 price target for the company. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $23.00.

ILLEGAL ACTIVITY WARNING: “Rhumbline Advisers Sells 1,242 Shares of GlycoMimetics Inc (NASDAQ:GLYC)” was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.watchlistnews.com/rhumbline-advisers-sells-1242-shares-of-glycomimetics-inc-nasdaqglyc/3039228.html.

GlycoMimetics Profile

GlycoMimetics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company's advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and is in a Phase III clinical trial, conducted by its strategic collaboration with Pfizer Inc It is also developing uproleselan, an E-selectin antagonist that is evaluated in a Phase I/II clinical trial as a potential treatment for acute myeloid leukemia (AML), as well as Phase III trial to treat relapsed/refractory AML.

Read More: Why are percentage gainers important?

Want to see what other hedge funds are holding GLYC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlycoMimetics Inc (NASDAQ:GLYC).

Institutional Ownership by Quarter for GlycoMimetics (NASDAQ:GLYC)

Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with MarketBeat.com's FREE daily email newsletter.